<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01959425</url>
  </required_header>
  <id_info>
    <org_study_id>OAT-149</org_study_id>
    <nct_id>NCT01959425</nct_id>
  </id_info>
  <brief_title>Oral Anticoagulation Therapy Pilot Study</brief_title>
  <acronym>OAT</acronym>
  <official_title>Safety of Oral Anticoagulation Therapy Withdrawal After Successful Cardiac Ablation in Patients With Atrial Fibrillation and Associated High Risk Factors for Embolic Events (OAT Pilot Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biosense Webster, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biosense Webster, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to determine the safety of discontinuing oral anticoagulation&#xD;
      therapy in high risk patients who have had a successful cardiac ablation and remain AF&#xD;
      recurrence free for 3 months post ablation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients undergoing successful cardiac ablation for atrial fibrillation who remain AF&#xD;
      recurrence-free 3 months after successful ablation and continue to meet the&#xD;
      inclusion/exclusion criteria will be screened for enrollment in the trial. After fulfilling&#xD;
      all of the inclusion/exclusion criteria, patients who consent to participate in the study and&#xD;
      remain AF recurrence-free will be randomized to one of two study arms: (1) OAT Withdrawal&#xD;
      (Test) Group or (2) OAT (Control) Group and participate in the Evaluation Period (12 months).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date type="Actual">April 17, 2013</start_date>
  <completion_date type="Actual">October 7, 2019</completion_date>
  <primary_completion_date type="Actual">October 7, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Occurrence of Any Major Thromboembolic Event</measure>
    <time_frame>12 months</time_frame>
    <description>Composite endpoint represented by the occurrence of any major thromboembolic event (stroke [i.e., ischemic, hemorrhagic or cryptogenic] that is an acute onset of a focal neurologic deficit of presumed vascular origin lasting for ≥24 hours or resulting in death) or major hemorrhagic complication (major bleeding) during the 12-month Evaluation Period.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Minor Bleeds</measure>
    <time_frame>12 months</time_frame>
    <description>Any clinical bleed that does not meet criteria for a major hemorrhagic event during the 12-month Evaluation Period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Hospitalized With Any Thromboembolic or Major Hemorrhagic Event</measure>
    <time_frame>12 months</time_frame>
    <description>Hospitalization due to any thromboembolic or major hemorrhagic event during the 12-month Evaluation Period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Expired Participants</measure>
    <time_frame>12 months</time_frame>
    <description>All cause mortality during the 12-month Evaluation Period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean SF-36 Quality of Life Scores of Participants at Baseline, 3 Months, and 12 Months: Physical Component Summary (PCS)</measure>
    <time_frame>Baseline, 3 months, 12 months</time_frame>
    <description>The 36-Item Short Form Health Survey (SF-36) is a validated health-related quality of life (HRQOL) tool used to measure the physical and mental health status of the study population. The SF-36 consists of eight scaled scores, which are the weighted sums of the questions in their section. Each scale is directly transformed into a 0-100 score on the assumption that each question carries equal weight. Scores can be summed together to contribute to two summary scores, a physical component score and a mental component score. The lower the score, the more disability.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean SF-36 Quality of Life Scores of Participants at Baseline, 3 Months, and 12 Months: Mental Component Summary (MCS)</measure>
    <time_frame>Baseline, 3 months, 12 months</time_frame>
    <description>The 36-Item Short Form Health Survey (SF-36) is a validated health-related quality of life (HRQOL) tool used to measure the physical and mental health status of the study population. The SF-36 consists of eight scaled scores, which are the weighted sums of the questions in their section. Each scale is directly transformed into a 0-100 score on the assumption that each question carries equal weight. Scores can be summed together to contribute to two summary scores, a physical component score and a mental component score. The lower the score, the more disability.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Atrial Fibrillation Recurrence</measure>
    <time_frame>12 months</time_frame>
    <description>Recurrence of atrial fibrillation during the 12-month Evaluation Period. Subjects with recurrence of atrial fibrillation were immediately exited from the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Repeat Ablation</measure>
    <time_frame>12 months</time_frame>
    <description>Repeat ablations performed due to recurrence of atrial fibrillation during the 12-month Evaluation Period. Subjects that required a repeat ablation were immediately exited from the study.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Paroxysmal Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Off OAT Group (Test)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Discontinuation of OAT Therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>On OAT Group (Control)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Continuation of OAT Therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Off OAT Group (Test)</intervention_name>
    <description>Discontinuation of OAT Therapy</description>
    <arm_group_label>Off OAT Group (Test)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>On OAT Group (Control)</intervention_name>
    <description>Continuation of OAT Therapy</description>
    <arm_group_label>On OAT Group (Control)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Successful cardiac ablation for AF&#xD;
&#xD;
          2. Documented freedom from AF recurrence (symptomatic or asymptomatic arrhythmic&#xD;
             recurrences lasting longer than 30 seconds) 3 months after successful cardiac ablation&#xD;
             (AF recurrence during 3-month blanking period is excluded).&#xD;
&#xD;
          3. Patient must have been on a commercially approved anticoagulation therapy for at least&#xD;
             two (2) months prior to randomization in the OAT Study.&#xD;
&#xD;
          4. CHADS2 score ≥ 2 or CHA2DS2-VASc score (≥3)&#xD;
&#xD;
          5. Left ventricular ejection fraction &gt; 25%&#xD;
&#xD;
          6. LA size &lt; 65&#xD;
&#xD;
          7. High risk for thromboembolic events (i.e., CHADS2 score ≥ 2 or CHA2DS2-VASc score ≥ 3)&#xD;
             and require OAT before undergoing cardiac ablation&#xD;
&#xD;
          8. Able and willing to comply with all pre- and follow-up testing and requirements&#xD;
&#xD;
          9. Signed informed consent form&#xD;
&#xD;
         10. Age 18 years or older&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. OAT required for reasons not related to AF (i.e., prosthetic valve, PV stenosis,&#xD;
             previous pulmonary embolism, presence of spontaneous echo contrast [SEC] at standard&#xD;
             echo performed at 3-months follow-up).&#xD;
&#xD;
          2. Any cardiac surgery within the past 60 days (2 months) or valvular cardiac surgical&#xD;
             procedure at any time (i.e., ventriculotomy, atriotomy, and valve repair or&#xD;
             replacement and presence of a prosthetic valve)&#xD;
&#xD;
          3. Previous myocardial infarction (MI) or a percutaneous coronary intervention PCI within&#xD;
             the past 3 months&#xD;
&#xD;
          4. Awaiting cardiac transplantation or other cardiac surgery within the next 365 days (12&#xD;
             months)&#xD;
&#xD;
          5. Documented left atrial thrombus&#xD;
&#xD;
          6. Significant pulmonary disease, (e.g., restrictive pulmonary disease, constrictive or&#xD;
             COPD) or any other disease or malfunction of the lungs or respiratory system that&#xD;
             produces chronic symptoms&#xD;
&#xD;
          7. Significant medical problem that in the opinion of the investigator would preclude&#xD;
             enrollment in this study&#xD;
&#xD;
          8. Women who are pregnant (as evidenced by pregnancy test if pre-menopausal)&#xD;
&#xD;
          9. Acute illness or active systemic infection or sepsis&#xD;
&#xD;
         10. Unstable angina&#xD;
&#xD;
         11. Contraindication to anticoagulation (i.e., heparin, warfarin or another commercially&#xD;
             available anticoagulation medication)&#xD;
&#xD;
         12. History of blood clotting or bleeding abnormalities&#xD;
&#xD;
         13. Life expectancy less than 360 days (12 months)&#xD;
&#xD;
         14. Uncontrolled Heart Failure or NYHA Class III or IV heart failure&#xD;
&#xD;
         15. Enrollment in a clinical study evaluating another device or drug, within the past 6&#xD;
             months&#xD;
&#xD;
         16. Unable or unwilling to comply with protocol requirements&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrea Natale, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Texas Cardiac Arrhythmia Research Foundation</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Antonio Raviele, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dell'Angelo Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael Riley, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Karl Heinz Kuck, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hanseatisches Herzzentrum, Asklepios Klinik</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michel Haissaguerre, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Cardiologigue du Haut-Leveque</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pierre Jais, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Cardiologigue du Haut-Leveque</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sakis Themistoclakis, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dell'Angelo Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Kansas Hospitals</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MetroHealth Medical Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Cardiac Arrhythmia Research Foundation</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Le Centre Hospitalier de Bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <state>Pessac</state>
        <zip>33604</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asklepios Klinik St. Georg</name>
      <address>
        <city>Hamburg</city>
        <zip>20099</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale dell'Angelo</name>
      <address>
        <city>Mestre</city>
        <state>Venezia</state>
        <zip>30174</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>October 8, 2013</study_first_submitted>
  <study_first_submitted_qc>October 9, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 10, 2013</study_first_posted>
  <results_first_submitted>October 6, 2020</results_first_submitted>
  <results_first_submitted_qc>November 20, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">December 17, 2020</results_first_posted>
  <last_update_submitted>November 20, 2020</last_update_submitted>
  <last_update_submitted_qc>November 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Anticoagulation</keyword>
  <keyword>Oral</keyword>
  <keyword>Paroxysmal atrial fibrillation</keyword>
  <keyword>Patients post successful cardiac ablation</keyword>
  <keyword>Symptomatic high-burden paroxysmal AF</keyword>
  <keyword>3 months post procedure</keyword>
  <keyword>Remain free from AF recurrence</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 21, 2013</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/25/NCT01959425/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The first subject was enrolled April 17, 2013. The last subject was enrolled January 25, 2019.</recruitment_details>
      <pre_assignment_details>This was a prospective, multicenter, randomized, controlled, two arm, 1:1 design. Enrolled subjects N=80 (subjects signed informed consent). 63 subjects underwent study procedures, 17 subjects were excluded prior to randomization. According to protocol, enrolled subjects = subjects who sign the study's informed consent form.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Off OAT Group (Test)</title>
          <description>Discontinuation of OAT Therapy</description>
        </group>
        <group group_id="P2">
          <title>On OAT Group (Control)</title>
          <description>Continuation of OAT Therapy</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
                <participants group_id="P2" count="31"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Discontinued Subjects</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Off OAT Group (Test)</title>
          <description>Discontinuation of OAT Therapy</description>
        </group>
        <group group_id="B2">
          <title>On OAT Group (Control)</title>
          <description>Continuation of OAT Therapy</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="32"/>
            <count group_id="B2" value="31"/>
            <count group_id="B3" value="63"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67.7" spread="5.85"/>
                    <measurement group_id="B2" value="66.0" spread="11.09"/>
                    <measurement group_id="B3" value="66.9" spread="8.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="52"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="52"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Occurrence of Any Major Thromboembolic Event</title>
        <description>Composite endpoint represented by the occurrence of any major thromboembolic event (stroke [i.e., ischemic, hemorrhagic or cryptogenic] that is an acute onset of a focal neurologic deficit of presumed vascular origin lasting for ≥24 hours or resulting in death) or major hemorrhagic complication (major bleeding) during the 12-month Evaluation Period.</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Off OAT Group (Test)</title>
            <description>Discontinuation of OAT Therapy</description>
          </group>
          <group group_id="O2">
            <title>On OAT Group (Control)</title>
            <description>Continuation of OAT Therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Occurrence of Any Major Thromboembolic Event</title>
          <description>Composite endpoint represented by the occurrence of any major thromboembolic event (stroke [i.e., ischemic, hemorrhagic or cryptogenic] that is an acute onset of a focal neurologic deficit of presumed vascular origin lasting for ≥24 hours or resulting in death) or major hemorrhagic complication (major bleeding) during the 12-month Evaluation Period.</description>
          <units>Number of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Minor Bleeds</title>
        <description>Any clinical bleed that does not meet criteria for a major hemorrhagic event during the 12-month Evaluation Period.</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Off OAT Group (Test)</title>
            <description>Discontinuation of OAT Therapy</description>
          </group>
          <group group_id="O2">
            <title>On OAT Group (Control)</title>
            <description>Continuation of OAT Therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Minor Bleeds</title>
          <description>Any clinical bleed that does not meet criteria for a major hemorrhagic event during the 12-month Evaluation Period.</description>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O2" value="3.2" lower_limit="0.1" upper_limit="16.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Hospitalized With Any Thromboembolic or Major Hemorrhagic Event</title>
        <description>Hospitalization due to any thromboembolic or major hemorrhagic event during the 12-month Evaluation Period.</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Off OAT Group (Test)</title>
            <description>Discontinuation of OAT Therapy</description>
          </group>
          <group group_id="O2">
            <title>On OAT Group (Control)</title>
            <description>Continuation of OAT Therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Hospitalized With Any Thromboembolic or Major Hemorrhagic Event</title>
          <description>Hospitalization due to any thromboembolic or major hemorrhagic event during the 12-month Evaluation Period.</description>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.1" lower_limit="0.1" upper_limit="16.2"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Expired Participants</title>
        <description>All cause mortality during the 12-month Evaluation Period.</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Off OAT Group (Test)</title>
            <description>Discontinuation of OAT Therapy</description>
          </group>
          <group group_id="O2">
            <title>On OAT Group (Control)</title>
            <description>Continuation of OAT Therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Expired Participants</title>
          <description>All cause mortality during the 12-month Evaluation Period.</description>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean SF-36 Quality of Life Scores of Participants at Baseline, 3 Months, and 12 Months: Physical Component Summary (PCS)</title>
        <description>The 36-Item Short Form Health Survey (SF-36) is a validated health-related quality of life (HRQOL) tool used to measure the physical and mental health status of the study population. The SF-36 consists of eight scaled scores, which are the weighted sums of the questions in their section. Each scale is directly transformed into a 0-100 score on the assumption that each question carries equal weight. Scores can be summed together to contribute to two summary scores, a physical component score and a mental component score. The lower the score, the more disability.</description>
        <time_frame>Baseline, 3 months, 12 months</time_frame>
        <population>The number of participants analyzed at each time point reflects the number of surveys collected at that time point for each group. Participants may have refused to complete the survey, or were exited from the study prior to the visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Off OAT Group (Test)</title>
            <description>Discontinuation of OAT Therapy</description>
          </group>
          <group group_id="O2">
            <title>On OAT Group (Control)</title>
            <description>Continuation of OAT Therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Mean SF-36 Quality of Life Scores of Participants at Baseline, 3 Months, and 12 Months: Physical Component Summary (PCS)</title>
          <description>The 36-Item Short Form Health Survey (SF-36) is a validated health-related quality of life (HRQOL) tool used to measure the physical and mental health status of the study population. The SF-36 consists of eight scaled scores, which are the weighted sums of the questions in their section. Each scale is directly transformed into a 0-100 score on the assumption that each question carries equal weight. Scores can be summed together to contribute to two summary scores, a physical component score and a mental component score. The lower the score, the more disability.</description>
          <population>The number of participants analyzed at each time point reflects the number of surveys collected at that time point for each group. Participants may have refused to complete the survey, or were exited from the study prior to the visit.</population>
          <units>Points on SF-36 scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Mean Score at Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="31"/>
                    <count group_id="O2" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.8" spread="8.56"/>
                    <measurement group_id="O2" value="50.0" spread="8.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean Score at 3 Months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="28"/>
                    <count group_id="O2" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.3" spread="6.85"/>
                    <measurement group_id="O2" value="50.3" spread="8.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean Score at 12 Months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.3" spread="8.60"/>
                    <measurement group_id="O2" value="50.0" spread="7.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean SF-36 Quality of Life Scores of Participants at Baseline, 3 Months, and 12 Months: Mental Component Summary (MCS)</title>
        <description>The 36-Item Short Form Health Survey (SF-36) is a validated health-related quality of life (HRQOL) tool used to measure the physical and mental health status of the study population. The SF-36 consists of eight scaled scores, which are the weighted sums of the questions in their section. Each scale is directly transformed into a 0-100 score on the assumption that each question carries equal weight. Scores can be summed together to contribute to two summary scores, a physical component score and a mental component score. The lower the score, the more disability.</description>
        <time_frame>Baseline, 3 months, 12 months</time_frame>
        <population>The number of participants analyzed at each time point reflects the number of surveys collected at that time point for each group. Participants may have refused to complete the survey, or were exited from the study prior to the visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Off OAT Group (Test)</title>
            <description>Discontinuation of OAT Therapy</description>
          </group>
          <group group_id="O2">
            <title>On OAT Group (Control)</title>
            <description>Continuation of OAT Therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Mean SF-36 Quality of Life Scores of Participants at Baseline, 3 Months, and 12 Months: Mental Component Summary (MCS)</title>
          <description>The 36-Item Short Form Health Survey (SF-36) is a validated health-related quality of life (HRQOL) tool used to measure the physical and mental health status of the study population. The SF-36 consists of eight scaled scores, which are the weighted sums of the questions in their section. Each scale is directly transformed into a 0-100 score on the assumption that each question carries equal weight. Scores can be summed together to contribute to two summary scores, a physical component score and a mental component score. The lower the score, the more disability.</description>
          <population>The number of participants analyzed at each time point reflects the number of surveys collected at that time point for each group. Participants may have refused to complete the survey, or were exited from the study prior to the visit.</population>
          <units>Points on SF-36 scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Mean Score at Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="31"/>
                    <count group_id="O2" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.5" spread="8.33"/>
                    <measurement group_id="O2" value="54.8" spread="8.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean Score at 3 Months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="28"/>
                    <count group_id="O2" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.8" spread="9.94"/>
                    <measurement group_id="O2" value="53.7" spread="10.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean Score at 12 Months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.2" spread="8.70"/>
                    <measurement group_id="O2" value="53.5" spread="9.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Atrial Fibrillation Recurrence</title>
        <description>Recurrence of atrial fibrillation during the 12-month Evaluation Period. Subjects with recurrence of atrial fibrillation were immediately exited from the study.</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Off OAT Group (Test)</title>
            <description>Discontinuation of OAT Therapy</description>
          </group>
          <group group_id="O2">
            <title>On OAT Group (Control)</title>
            <description>Continuation of OAT Therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Atrial Fibrillation Recurrence</title>
          <description>Recurrence of atrial fibrillation during the 12-month Evaluation Period. Subjects with recurrence of atrial fibrillation were immediately exited from the study.</description>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.8" lower_limit="7.2" upper_limit="36.4"/>
                    <measurement group_id="O2" value="12.9" lower_limit="3.6" upper_limit="29.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Repeat Ablation</title>
        <description>Repeat ablations performed due to recurrence of atrial fibrillation during the 12-month Evaluation Period. Subjects that required a repeat ablation were immediately exited from the study.</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Off OAT Group (Test)</title>
            <description>Discontinuation of OAT Therapy</description>
          </group>
          <group group_id="O2">
            <title>On OAT Group (Control)</title>
            <description>Continuation of OAT Therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Repeat Ablation</title>
          <description>Repeat ablations performed due to recurrence of atrial fibrillation during the 12-month Evaluation Period. Subjects that required a repeat ablation were immediately exited from the study.</description>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>12 Months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Off OAT Group (Test)</title>
          <description>Discontinuation of OAT Therapy</description>
        </group>
        <group group_id="E2">
          <title>On OAT Group (Control)</title>
          <description>Continuation of OAT Therapy</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial Fibrillation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Arterial bypass thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rotator cuff syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Vocal cord paralysis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Joint Fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Any results communications proposed to be published or presented shall be submitted to Sponsor at least 60 days prior to public release to permit Sponsor to direct removal of any confidential information contained therein. The first results communications should be a multicenter, joint publication. If a multicenter publication is not submitted by the Sponsor or designee within 12 months of the Study conclusion, PIs may publish results from their institution in accordance with the above.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Stephanie Lyke</name_or_title>
      <organization>Biosense Webster Inc.</organization>
      <phone>(949) 285-7966</phone>
      <email>SLyke@its.jnj.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

